Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease
Could Merck/Kelun Come Out On Top?
Executive Summary
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.